Progress in molecular-based management of differentiated thyroid cancer
M Xing, BR Haugen, M Schlumberger - The Lancet, 2013 - thelancet.com
Substantial developments have occurred in the past 5–10 years in clinical translational
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …
research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and …
Molecular targets of tyrosine kinase inhibitors in thyroid cancer
P Fallahi, SM Ferrari, MR Galdiero, G Varricchi… - Seminars in cancer …, 2022 - Elsevier
Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer
M Schlumberger, M Tahara, LJ Wirth… - … England Journal of …, 2015 - Mass Medical Soc
Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor …
and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor …
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
MS Brose, CM Nutting, B Jarzab, R Elisei, S Siena… - The Lancet, 2014 - thelancet.com
Background Patients with radioactive iodine (131 I)-refractory locally advanced or metastatic
differentiated thyroid cancer have a poor prognosis because of the absence of effective …
differentiated thyroid cancer have a poor prognosis because of the absence of effective …
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
S Leboulleux, L Bastholt, T Krause… - The lancet …, 2012 - thelancet.com
Background No effective standard treatment exists for patients with radioiodine-refractory,
advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of …
advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of …
[HTML][HTML] Novel treatments for anaplastic thyroid carcinoma
SM Ferrari, G Elia, F Ragusa, I Ruffilli, C La Motta… - Gland …, 2020 - ncbi.nlm.nih.gov
Anaplastic thyroid cancer (ATC) is one of the deadliest human cancers and it is less than 2%
of thyroid carcinomas (TCs). The standard treatment of ATC includes surgical debulking …
of thyroid carcinomas (TCs). The standard treatment of ATC includes surgical debulking …
Novel therapeutics in radioactive iodine-resistant thyroid cancer
T Fullmer, ME Cabanillas, M Zafereo - Frontiers in Endocrinology, 2021 - frontiersin.org
Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until
recently, there were limited therapeutic options. However, over the last decade our …
recently, there were limited therapeutic options. However, over the last decade our …
Thyroid carcinoma, version 2.2014
RM Tuttle, RI Haddad, DW Ball, D Byrd… - Journal of the National …, 2014 - jnccn.org
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN
Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid …
Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid …
Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine
T Jaber, SG Waguespack, ME Cabanillas… - The Journal of …, 2018 - academic.oup.com
Context Many differentiated thyroid cancers (DTC) dedifferentiate and become radioactive
iodine (RAI)–refractory (RAIR) with worse outcomes. Targeted therapy (TTx) may …
iodine (RAI)–refractory (RAIR) with worse outcomes. Targeted therapy (TTx) may …
Redifferentiation of radioiodine-refractory thyroid cancers
C Buffet, J Wassermann, F Hecht… - Endocrine-Related …, 2020 - erc.bioscientifica.com
The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …